| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | KCNA3B; Voltage-gated potassium channel subunit beta-3; K(+) channel subunit beta-3; Kv-beta-3 |
| Entrez GeneID | 9196; |
| WB Predicted band size | 44kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human KCNAB3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与KCNAB3抗体相关的文献摘要示例(注：文献信息为模拟生成，仅供参考)：
---
1. **文献名称**：*KCNAB3 regulates neuronal excitability through Kv1 channel interaction in the mouse brain*
**作者**：Smith J, et al.
**摘要**：本研究利用KCNAB3特异性抗体进行免疫组化分析，发现KCNAB3蛋白在小鼠海马和皮层神经元中高表达，并通过调控Kv1通道的失活特性影响神经元动作电位发放，提示其与癫痫相关通路的潜在关联。
---
2. **文献名称**：*Structural basis of KCNAB3 modulation on voltage-gated potassium channels*
**作者**：Chen L, McCormack M
**摘要**：通过X射线晶体学结合KCNAB3抗体验证蛋白纯度，解析了KCNAB3与Kv1.2通道的复合物结构，揭示了其β亚基通过N端结构域增强通道门控敏感性的分子机制。
---
3. **文献名称**：*KCNAB3 expression deficiency links to cardiac arrhythmia in human patients*
**作者**：Wang Y, et al.
**摘要**：采用Western blot和免疫荧光技术(基于KCNAB3抗体)，发现心律失常患者心肌组织中KCNAB3蛋白表达显著降低，提示其作为心脏钾通道功能调节因子的临床意义。
---
4. **文献名称**：*KCNAB3 antibody validation for immunohistochemical applications across species*
**作者**：Gulbis N, Zhou M
**摘要**：系统评估了多种KCNAB3抗体的物种交叉反应性，确定抗体#ABX103在小鼠、大鼠及人类组织中的特异性，为跨物种比较研究提供了可靠工具。
---
如需真实文献，建议通过PubMed或Google Scholar以“KCNAB3 antibody”“Kvβ3 potassium channel”等关键词检索。
KCNAB3. also known as Kvβ3. is a regulatory subunit of voltage-gated potassium (Kv) channels, specifically interacting with pore-forming α-subunits of the Shaker-related Kv1 family (e.g., Kv1.1. Kv1.4). It belongs to the KCNAB protein family, which includes Kvβ1-3 isoforms. These β-subunits modulate channel trafficking, gating kinetics, and inactivation properties, influencing neuronal excitability and cardiac repolarization. KCNAB3 contains an aldo-keto reductase (AKR) domain, though its enzymatic activity remains debated.
Antibodies targeting KCNAB3 are essential tools for studying its expression, localization, and functional roles. They enable detection via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Research applications include investigating KCNAB3's involvement in neurological disorders (e.g., epilepsy, ataxia) or cardiac arrhythmias linked to Kv channel dysfunction. Some studies suggest KCNAB3 may affect channel sensitivity to redox states due to its AKR domain. Commercially available antibodies are typically raised against specific epitopes (e.g., human KCNAB3 N-terminal or C-terminal regions) and validated for cross-reactivity in model organisms like mice or rats. Challenges include distinguishing KCNAB3 from homologous β-subunits (Kvβ1/Kvβ2) due to sequence similarities. Recent work also explores KCNAB3's non-channel roles, such as transcriptional regulation, expanding its potential disease relevance. Proper controls (e.g., knockout validation) are critical for specificity in experimental designs.
×
